Navigation Links
China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
Date:1/14/2008

NEW YORK and HAIKOU, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign. Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.

HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.

China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases. Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.

"This is an exciting time for China Pharma Holdings, Inc. as we continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma Holdings, Inc. "After careful review, we selected HC International to ensure that our shareholders and members of the investment community are properly informed of our growth strategy and competitive advantages, including our focus on addressing high mortality diseases in China which includes targeting specific patient populations. The team at HC International is well respected and has a proven track record of representing many successful China based, US listed companies, including those operating in the Pharmaceutical Industry. We are confident they will help us to improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors.''

"China Pharma is a very profitable pharmaceutical manufacturer in China that is well positioned to capitalize on its core strengths to address a large emerging market opportunity," said Matthew Hayden, President of HC International. "Given its strong management team, research and development expertise, and diverse product pipeline of potential new drugs, China Pharma presents an attractive opportunity for investors by possessing the necessary assets to build shareholder value over the long term.''

About China Pharma Holdings, Inc., Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

About HC International, Inc.

HC International is a focused and dedicated organization that acts as a premier informational resource for institutional investors, hedge funds, buy and sell-side analysts, small to large brokerage firms and accredited investors. HC International helps their clients' companies package their corporate information in a clear, concise and consistent manner while facilitating introductions to the right investors at the most opportune time. For further information, please contact HC International directly, or visit the Company's Web site at http://www.hcinternational.net .

For more information, please contact:

China Pharma Holdings, Inc.

Sophia Yu

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
(Date:5/23/2016)... Ohio (PRWEB) , ... May 23, 2016 , ... ... Trends That Will Drive Precision Farming in 2017 and Beyond. The paper outlines ... practitioners in the precision ag industry. , “We’ve witnessed a lot of highs ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):